StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.18 | $2.21 | +1.38% | 0.2M |
| 05-12 | $2.18 | $2.20 | +0.92% | 0.3M |
| 05-13 | $2.20 | $2.03 | -7.73% | 0.2M |
| 05-14 | $2.03 | $1.95 | -3.94% | 0.2M |
| 05-15 | $1.92 | $1.97 | +2.60% | 0.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $44.94M | $192.22M | $145.81M | $97.86M |
Operating Income | $3.17M | $35.55M | $28.72M | $20.45M |
Net Income | $2.28M | $27.05M | $25.09M | $16.90M |
EPS (Diluted) | $0.06 | $0.74 | $0.68 | $0.46 |
Total Assets | $89.03M | $107.61M | $111.32M | $104.80M |
Total Liabilities | $136.99M | $158.01M | $176.79M | $183.64M |
Cash & Equivalents | $5.32M | $24.12M | $28.05M | $19.60M |
Free Cash Flow OCF − CapEx | $3.54M | $30.18M | $23.69M | $10.11M |
Shares Outstanding | 36.00M | 36.67M | 36.87M | 36.96M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.